-$0.28 Earnings Per Share Expected for Solid Biosciences Inc. (NASDAQ:SLDB) This Quarter


Share on StockTwits

Brokerages expect Solid Biosciences Inc. (NASDAQ:SLDB) to announce ($0.28) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Solid Biosciences’ earnings. Solid Biosciences posted earnings of ($0.52) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 46.2%. The firm is scheduled to issue its next quarterly earnings results on Thursday, May 6th.

On average, analysts expect that Solid Biosciences will report full-year earnings of ($1.11) per share for the current fiscal year, with EPS estimates ranging from ($1.46) to ($0.72). For the next year, analysts expect that the firm will post earnings of ($0.98) per share, with EPS estimates ranging from ($1.35) to ($0.61). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Solid Biosciences.

Solid Biosciences (NASDAQ:SLDB) last released its quarterly earnings results on Sunday, March 14th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.03.

Several research firms have weighed in on SLDB. Zacks Investment Research lowered shares of Solid Biosciences from a “hold” rating to a “sell” rating in a research note on Wednesday, February 10th. Chardan Capital upped their price objective on shares of Solid Biosciences from $12.50 to $20.00 and gave the stock a “buy” rating in a report on Monday, March 22nd. Barclays began coverage on shares of Solid Biosciences in a report on Monday, March 15th. They set an “overweight” rating and a $13.00 price objective for the company. Credit Suisse Group upped their price objective on shares of Solid Biosciences from $7.00 to $8.00 and gave the stock a “neutral” rating in a report on Monday, March 22nd. Finally, SVB Leerink raised shares of Solid Biosciences from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $3.00 to $15.00 in a report on Monday, March 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $11.04.

In other news, Director Ra Capital Management, L.P. bought 2,206,685 shares of the company’s stock in a transaction that occurred on Friday, March 19th. The stock was acquired at an average price of $5.75 per share, for a total transaction of $12,688,438.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Carl Ashley Morris sold 23,398 shares of the stock in a transaction dated Friday, March 12th. The stock was sold at an average price of $8.84, for a total transaction of $206,838.32. Following the sale, the insider now owns 287,301 shares of the company’s stock, valued at approximately $2,539,740.84. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 44,486 shares of company stock valued at $336,319. Corporate insiders own 31.20% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System increased its position in shares of Solid Biosciences by 16.5% during the 3rd quarter. California State Teachers Retirement System now owns 36,076 shares of the company’s stock worth $73,000 after purchasing an additional 5,102 shares in the last quarter. First Trust Advisors LP grew its holdings in Solid Biosciences by 25.4% during the 4th quarter. First Trust Advisors LP now owns 84,824 shares of the company’s stock worth $643,000 after acquiring an additional 17,208 shares during the last quarter. Rhumbline Advisers grew its holdings in Solid Biosciences by 23.5% during the 4th quarter. Rhumbline Advisers now owns 35,001 shares of the company’s stock worth $265,000 after acquiring an additional 6,661 shares during the last quarter. ExodusPoint Capital Management LP bought a new stake in Solid Biosciences during the 4th quarter worth about $348,000. Finally, Citigroup Inc. grew its holdings in Solid Biosciences by 62.8% during the 4th quarter. Citigroup Inc. now owns 9,465 shares of the company’s stock worth $72,000 after acquiring an additional 3,652 shares during the last quarter. Institutional investors and hedge funds own 42.73% of the company’s stock.

Shares of SLDB stock traded up $0.10 during trading hours on Thursday, reaching $4.98. 16,905 shares of the stock traded hands, compared to its average volume of 1,705,740. Solid Biosciences has a 1-year low of $1.93 and a 1-year high of $11.58. The business has a fifty day moving average price of $7.20 and a 200 day moving average price of $5.62. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $532.25 million, a PE ratio of -2.37 and a beta of 1.10.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to derive functional dystrophin protein expression in patients' muscles.

Recommended Story: How mutual funds make money

Get a free copy of the Zacks research report on Solid Biosciences (SLDB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Solid Biosciences (NASDAQ:SLDB)

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.